Track Excelsior Biopharma's operating income ($-180M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2026
Trailing 12 months ending Sep 30, 2026
The latest operating income for 6496.TWO is $-180M as of September 2026. That compares with $-150M in the prior-year period — down 17.3% year over year. Investors often review this figure alongside Excelsior Biopharma's historical trend and sector peers before judging valuation or financial health.
Over the past year, 6496.TWO's operating income moved from $-150M to $-180M — a 17.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Excelsior Biopharma's operating scale or balance-sheet position.
A operating income figure of $-180M for 6496.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting 6496.TWO's operating income ($-180M), review year-over-year change from $-150M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.